Leveraging mature hepatic targeting strategies and optimized oligonucleotide modification systems, Youngen’s liver-targeted delivery pipelines enable efficient, stable, and high-specificity accumulation of RNAi therapeutics in hepatocytes with a favorable safety profile. Differentiated from conventional single-target therapies, our metabolic pipelines adopt a dual-target therapeutic strategy, simultaneously intervening in core pathogenic genes and key metabolic signaling pathways that drive lipid overaccumulation, glucose metabolic disorder. We aim to provide novel and potent RNAi therapeutic solutions for refractory obesity and chronic metabolic diseases.
